APP and Alzheimer disease: Backfilling against multiple enzymes involved in N-glycosylation and O-glycosylation that are known to be down-regulated in AD cells is also a potential AD treatment that may ameliorate AD symptoms by boosting the stability of APP, slowing down the processing and transport of aberrant proteins, and in a number of other ways.